We are an oncology company that is focused on the development of oncolytic viruses that are able to selectively kill cancer cells and secondarily illicit a natural immune response. SATOR Therapeutics has developed a library of 30 oncolytic viruses which have demonstrated a differential response across multiple cancers where several viruses have shown efficacy across multiple indications. The viruses are non-engineered, non-pathogenic and can be administered systemically via IV. These viruses were collected over decades of research and by combining them can overcome many of the challenges associated with a single oncolytic virus and neutralizing antibodies while avoiding the safety problems associated with engineered viruses. Additionally, SATOR has developed a diagnostic approach for predicting efficacy as well as a next-generation delivery approach using dendritic cells.
Company Details
- Employees
- 3
- Founded
- 2018
- Address
- Cleveland, Ohio 44106, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://satortx.com
- Keywords
- IT Consulting.
- HQ
- Cleveland, Ohio
Sator Therapeutics Questions
Sator Therapeutics's website is http://satortx.com
Sator Therapeutics's LinkedIn profile is https://www.linkedin.com/company/sator-therapeutics
Sator Therapeutics has
3 employees.
View email and phone details for 3
employees at Sator Therapeutics.
Sator Therapeutics's industry is
Pharmaceutical Manufacturing
Sator Therapeutics's top competitors are
Latigo Biotherapeutics, Inc.,
Eqlipse Technologies, A Bluehalo Company,
Aim Biotech,
Globeimmune, Inc.,
Mattek Life Sciences,
Mimetas,
Universal Cells,
New Jersey Innovation Institute,
Biolabs For Advanced Therapeutics Philadelphia,
Visikol.
Sator Therapeutics's categories are Pharmaceutical Manufacturing
Sator Therapeutics's founding year is 2018
